Q-omics provides the consensus-scored EPB41L4A-AS1 profile across patient tissues and cancer cell-line models. EPB41L4A-AS1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EPB41L4A-AS1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, EPB41L4A-AS1 RNA expression shows 17,575 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where EPB41L4A-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPB41L4A-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPB41L4A-AS1 survival associations across molecular data types. EPB41L4A-AS1 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPB41L4A-AS1 RNA expression–survival associations across cancer types. High EPB41L4A-AS1 expression shows unfavorable associations in ACC and OV, but favorable associations in KIRC, MESO, UVM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EPB41L4A-AS1 RNA expression.
This table summarizes EPB41L4A-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EPB41L4A-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPB41L4A-AS1 shows lower tumor expression in UCEC, BRCA and BLCA and higher tumor expression in KIRC, COAD and LIHC. The KIRC box plot shows higher EPB41L4A-AS1 RNA expression in tumor versus normal tissue (log2 FC = +1.360, t-test p < 0.001).
This table shows molecular features associated with EPB41L4A-AS1 in patient tissues and cancer cell lines. In patient samples, EPB41L4A-AS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EPB41L4A-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC.
